Suchergebnisse - "Langer, Jakob"

PubPharm (11)

1

Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US

enthalten in: Journal of medical economics | 2018

von Dempsey, M. | Mocarski, M. | Langer, J. | +1

2

Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S

enthalten in: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists | 2018

von Dempsey, M. | Mocarski, M. | Langer, J. | +1

3

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

enthalten in: Advances in therapy | 2017

von Hunt, B. | Mocarski, M. | Valentine, W. | +1

ErratumIn: Adv Ther. 2017 Jun;34(6):1500-1501. - PMID 28523624

4

Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States

enthalten in: Journal of medical economics | 2016

von Durden, E. | Lenhart, G. | Lopez-Gonzalez, L. | +2

5

Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide : a retrospective cohort study

enthalten in: Advances in therapy | 2015

von Buysman, E. | Liu, F. | Hammer, M. | +1

6

Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States : a retrospective cohort study

enthalten in: Advances in therapy | 2014

von Chitnis, A. | Ganz, M. | Benjamin, N. | +2

7

Real-world cost-effectiveness : lower cost of treating patients to glycemic goal with liraglutide versus exenatide

enthalten in: Advances in therapy | 2014

von DeKoven, M. | Lee, W. | Bouchard, J. | +2

8

Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg

enthalten in: Clinical therapeutics | 2013

von Malmenäs, M. | Bouchard, J. | Langer, J.

9

Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States

enthalten in: Journal of managed care pharmacy : JMCP | 2013

von Langer, J. | Hunt, B. | Valentine, W.

10

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes : a CORE Diabetes Model analysis

enthalten in: Journal of medical economics | 2012

von Lee, W. | Samyshkin, Y. | Langer, J. | +1